Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients.

Brahmer JR, Long GV, Hamid O, Garon EB, Herbst RS, Andre T, Armand P, Bajorin D, Bellmunt J, Burtness B, Choueiri TK, Cohen EEW, Diaz LA Jr, Shitara K, Kulkarni G, McDermott D, Shah M, Tabernero J, Vogel A, Zinzani PL, Jafari N, Bird S, Snyder E, Gause C, Bracco OL, Pietanza MC, Gruber T, Ribas A

Open source

DOI: 10.1016/j.ejca.2024.113530
Published: 2024 Mar
Container: European journal of cancer (Oxford, England : 1990)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ejca.2024.113530,
  title = {Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients.},
  author = {Brahmer JR and Long GV and Hamid O and Garon EB and Herbst RS and Andre T and Armand P and Bajorin D and Bellmunt J and Burtness B and Choueiri TK and Cohen EEW and Diaz LA Jr and Shitara K and Kulkarni G and McDermott D and Shah M and Tabernero J and Vogel A and Zinzani PL and Jafari N and Bird S and Snyder E and Gause C and Bracco OL and Pietanza MC and Gruber T and Ribas A},
  year = {2024},
  journal = {European journal of cancer (Oxford, England : 1990)},
  doi = {10.1016/j.ejca.2024.113530},
  url = {https://doi.org/10.1016/j.ejca.2024.113530}
}

RIS

TY  - JOUR
TI  - Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients.
AU  - Brahmer JR
AU  - Long GV
AU  - Hamid O
AU  - Garon EB
AU  - Herbst RS
AU  - Andre T
AU  - Armand P
AU  - Bajorin D
AU  - Bellmunt J
AU  - Burtness B
AU  - Choueiri TK
AU  - Cohen EEW
AU  - Diaz LA Jr
AU  - Shitara K
AU  - Kulkarni G
AU  - McDermott D
AU  - Shah M
AU  - Tabernero J
AU  - Vogel A
AU  - Zinzani PL
AU  - Jafari N
AU  - Bird S
AU  - Snyder E
AU  - Gause C
AU  - Bracco OL
AU  - Pietanza MC
AU  - Gruber T
AU  - Ribas A
PY  - 2024
JO  - European journal of cancer (Oxford, England : 1990)
DO  - 10.1016/j.ejca.2024.113530
UR  - https://doi.org/10.1016/j.ejca.2024.113530
ER  -

APA

JR, B., GV, L., O, H., EB, G., RS, H., T, A., P, A., D, B., J, B., B, B., TK, C., EEW, C., Jr, D. L., K, S., G, K., D, M., M, S., J, T., A, V., PL, Z., N, J., S, B., E, S., C, G., OL, B., MC, P., T, G., & A, R. (2024). Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients.. European journal of cancer (Oxford, England : 1990). https://doi.org/10.1016/j.ejca.2024.113530

Source records

pubmed · retrieved 2026-09-26T12:42:33.158Z